Hansa Biopharma's Impressive 2024 Sales Growth: A Beacon of Hope in the Biopharma Sector

Hansa Biopharma, a leading biopharmaceutical company specializing in immune tolerance induction, has reported its full year and Q4 2024 financial results, showcasing remarkable growth and progress in its pipeline. The company's flagship product, IDEFIRIX®, demonstrated an 83% year-on-year increase in sales, excluding the impact of a provision for retroactive price adjustments linked to successful special early access programs following IDEFIRIX's launch in 2020. Including the provision, 2024 IDEFIRIX product sales totaled 140.1 MSEK, representing a 35% increase over the prior year. Total 2024 sales increased by 28% compared to the prior year, driven by the strong performance of IDEFIRIX across Europe.



The company's success can be attributed to several factors, including the ongoing commercial success of IDEFIRIX, the achievement of key pipeline milestones in priority therapy areas, and the positive results from clinical trials. The positive readout from the Phase 2 15-HMedIdeS study in Guillain-Barré Syndrome (GBS) and the indirect treatment comparison of imlifidase to the International Guillain-Barré Syndrome Outcome Study (IGOS) demonstrated the potential of imlifidase to address a significant unmet need in GBS. Additionally, the favorable 12-month analysis from the NICE-01 study of HNSA-5487 showed that the next-generation IgG cleaving molecule can very robustly and rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile.

Hansa Biopharma's pipeline progress continues with the completion of enrolment in the GOOD-IDES-02 Phase 3 study of imlifidase in anti-GBM and the initiation of a Phase 2 trial of imlifidase in Crigler-Najjar syndrome with pre-existing antibodies against adeno-associated (AAV) vectors in collaboration with Genethon. The company also announced the completion of enrolment in the US Phase 3 pivotal trial for imlifidase in kidney transplantation, with data readout expected in the second half of 2025.

Despite the strong full-year sales of IDEFIRIX, quarterly sales continue to fluctuate due to variations in European kidney allocation systems impacting the availability of organs to specific patients. However, the company's ongoing momentum in the clinical community and successful launch execution in Europe are expected to drive greater utilization of IDEFIRIX, contributing to sustained growth in the future.

In conclusion, Hansa Biopharma's impressive 2024 sales growth and pipeline progress demonstrate the company's potential as a leader in the biopharma sector. With a strong focus on immune tolerance induction and a robust pipeline, Hansa Biopharma is well-positioned to continue its growth trajectory and deliver value to investors. As the company continues to advance its pipeline and expand its market reach, it remains an attractive investment opportunity in the biopharma sector.